eral years, though it recently sought new public input on its CED guidance document. “I’m seeing big players in industry … make public comments that CED is good for innovation,” he said. Jacques also would like to see CED have greater breadth and flexibility so that not every new molecular indicator and LDT needs to be reviewed.

Medicare still has considerable local authority, Jacques pointed out, and local decisions do not necessarily apply nationwide. More collaborative review processes could help create greater nationwide consistency.



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement